[nc-udrp] WIPO 2 Report - INN's

["John Berryhill Ph.D. J.D." <john@johnberryhill.com>]

I apologize in advance if this is out of order, but I believe that
consideration of the WIPO 2 report is one of our agenda items.  The WIPO 2
report is available at:

http://wipo2.wipo.int/process2/report/

One of the recommendations of the WIPO 2 report is elimination from the
internet domain name system of International Non-proprietary Names of
pharmaceuticals.  These names, which include such terms as "xenon",
"testosterone", "methadone", "cesium chloride",  "sodium iodide", and the
like, are said to pose a risk to public health and safety when registered as
domain names.  There are 6,500 such INNs in five official languages, for a
total of 32,500 terms to be banned in each TLD, or 97,500 potential domain
names in .com, .net, and .org.

The actual number of names to be cancelled is dramatically less than that, as
I have just completed a study which shows 84% of English INN's to be
unregistered as domain names in .com alone.

However, due to the diversity of parties having such domain names, it may be
well for anyone participating in consideration of the WIPO 2 proposal to have
some familiarity with the domain name system abusers which are targeted by
the INN proposal.  A short table is included in the WIPO 2 report, but I have
found it to be oddly selective in the abusive registrants identified therein.
A more comprehensive study of INN's beginning with the letter "A" is posted
at

www.johnberryhill.com/abusers.html

and should provide the participants in this discussion with an opportunity to
become acquainted with the identity of these abusive domain name registrants,
and to resolve any conflicts of interest they may have.

If WIPO's INN proposal is adopted, then additional penalties, such as a
repayment to WIPO of administrative costs, should be imposed on
cybersquatters who have engaged in particularly notable stockpiling of these
abusive registrations, such as Glaxo SmithKline, Johnson & Johnson, ICI, and
Pharmacia AB.

Sincerely,

John Berryhill